The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development and validation of a prognostic model for advanced gastric and oesophageal carcinoma (AGOC) using individual patient data from two clinical trials.
 
Sayeda Naher
No Relationships to Disclose
 
David Espinoza
No Relationships to Disclose
 
Peter Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Genentech (Inst); InhibRx (Inst); InhibRx (Inst); Janssen-Cilag (Inst); MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Moderna.Inc; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Nick Pavlakis
Honoraria - Bayer; BeiGene; BeiGene; Pierre Fabre; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Duo Oncology; Gilead Sciences; Janssen Oncology; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Merck KGaA
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
David Goldstein
Honoraria - AstraZeneca; Boehringer Ingelheim; duo oncology; Merck; Sun Biopharma
Consulting or Advisory Role - amplicare; AstraZeneca; Boehringer Ingelheim; duo oncology; hC bioscience; Medison; MSD Oncology; Seagen; sun biopharma; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); pfizer (Inst); Zucero Therapeutics (Inst)
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Rebecca Mercieca-Bebber
No Relationships to Disclose
 
Katrin Sjoquist
Honoraria - Astellas Pharma; Bayer (Inst); BMS; Glenmark (Inst); Lisata (Inst); MSD; Novotech (Inst); SERVIER
Research Funding - Bayer (Inst)
Other Relationship - Novotech